Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Young Adult With Osteosarcoma of the Mandible and the Challenge in Management

Review of the Pediatric and Adult Literatures

Kuo, Christopher, MD*; Kent, Paul M., MD, FAAP

Journal of Pediatric Hematology/Oncology: January 2019 - Volume 41 - Issue 1 - p 21–27
doi: 10.1097/MPH.0000000000001332
Original Articles

Neoadjuvant chemotherapy for osteosarcoma of the jaw (OSJ) remains controversial despite being a standardized treatment in osteosarcoma of the long bones. We present a case of a 22-year-old male with OSJ and performed a retrospective systemic review of previously published literatures of OSJ. We identified 27 articles: 7% recommended neoadjuvant chemotherapy, 22% recommended adjuvant chemotherapy, 19% recommended both neoadjuvant and adjuvant chemotherapy, 33% recommended against chemotherapy and 19% stated the role of chemotherapy is unknown. The lack of consensus regarding the use of chemotherapy in OSJ, despite its benefits, demonstrates the need to establish a standardized algorithm for OSJ.

*Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, CA

Department of Pediatric Hematology/Oncology, Department of Pediatrics, Rush University Medical Center, Chicago, IL

Informed consent has been properly documented.

The authors declare no conflict of interest.

Reprints: Paul M. Kent, MD, FAAP, Department of Pediatrics, Medical Director, Sarcoma Program, Rush University Medical Center, Department of Pediatrics, Division of Hematology and Oncology, 1725 West Harrison Street, Suite 710, Chicago, IL 60612-3824 (e-mail: Paul_Kent@Rush.edu).

Received May 14, 2018

Accepted August 16, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.